Abstract
Objectives: This study was conducted to evaluate the effect of simvastatin (40 mg/day) as an adjuvant therapy to interferon beta (IFNb 1a, 30 mug once weekly) in relapsing-remitting multiple sclerosis patients, compared with placebo....................
Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1319